Literature DB >> 32671606

Evaluation of 30-day complication rates following vaginal anterior compartment repair with and without graft augmentation in a propensity score matched cohort.

Ryan Darvish1, Abigail Davenport1, Angela Dao1, Emily Slopnick1,2, Graham Chapman1,2, David Sheyn3.   

Abstract

OBJECTIVE: To determine if graft augmentation with anterior colporrhaphy (AC+G) is associated with higher complication rates compared to native tissue repair (AC).
MATERIALS AND METHODS: Retrospective cohort study using data from the ACS-NSQIP database between 2010 and 2017. CPT codes were used to identify women undergoing AC+G and AC. Propensity scores for the likelihood of undergoing AC+G were calculated and were used to match to women undergoing native tissue repair at a ratio of 1:2. The primary outcome was the composite complication rate. Descriptive statistics are reported as means with standard deviations for parametric data and as medians and interquartile ranges for non-parametric data. Pairwise comparisons were performed using Fisher's exact test, Wilcoxon rank-sum and Student's t test as appropriate. Multivariable logistic regression was then used to adjust for confounders to identify statistically significant factors associated with the likelihood of experiencing a complication after prolapse repair.
RESULTS: 582 women met inclusion criteria for AC+G and were matched with 1164 women undergoing AC. There were no differences in preoperative characteristics between groups. There was no difference in the composite complication rate, (10.8% vs. 8.5%, p = 0.13) between groups. Dependent functional status (aOR 4.31, 95% CI 1.96-13.58) was the strongest predictor of the likelihood of a complication: other significant predictors were operating time greater than 20 min (aOR 1.68, 95% CI 1.19-2.38) and ASA class greater than 2 (aOR 1.44, 95% CI 1.01-2.05).
CONCLUSION: There is no increase in 30-day complication rates in women undergoing AC+G compared to a matched cohort of those undergoing AC alone.

Entities:  

Keywords:  Anterior colporrhaphy; Pelvic organ prolapse; Propensity score; Trans-vaginal mesh

Year:  2020        PMID: 32671606     DOI: 10.1007/s00345-020-03360-3

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  7 in total

1.  Critical appraisal of the application of propensity score methods in the urology literature.

Authors:  Madhur Nayan; Robert J Hamilton; David N Juurlink; Antonio Finelli; Girish S Kulkarni; Peter C Austin
Journal:  BJU Int       Date:  2017-07-07       Impact factor: 5.588

Review 2.  Surgery for women with anterior compartment prolapse.

Authors:  Christopher Maher; Benjamin Feiner; Kaven Baessler; Corina Christmann-Schmid; Nir Haya; Julie Brown
Journal:  Cochrane Database Syst Rev       Date:  2016-11-30

3.  Outcomes of vaginal prolapse surgery among female Medicare beneficiaries: the role of apical support.

Authors:  Karyn S Eilber; Marianna Alperin; Aqsa Khan; Ning Wu; Chris L Pashos; J Quentin Clemens; Jennifer T Anger
Journal:  Obstet Gynecol       Date:  2013-11       Impact factor: 7.661

Review 4.  Surgical management of pelvic organ prolapse in women.

Authors:  Christopher Maher; Benjamin Feiner; Kaven Baessler; Corina Schmid
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

5.  Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score.

Authors:  Peter C Austin
Journal:  Am J Epidemiol       Date:  2010-08-28       Impact factor: 4.897

6.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.

Authors:  Peter C Austin
Journal:  Pharm Stat       Date:  2011 Mar-Apr       Impact factor: 1.894

7.  Vaginal repair with mesh versus colporrhaphy for prolapse: a randomised controlled trial.

Authors:  M Carey; P Higgs; J Goh; J Lim; A Leong; H Krause; A Cornish
Journal:  BJOG       Date:  2009-07-07       Impact factor: 6.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.